
Despite women making up half of the world's population, an increasingly smaller sum of the many billions of dollars spent on the research and development of new drugs goes to diseases related specifically to women.
This paradox is now being highlighted by Bioinnovation Institute (BII), which supports early-stage life science start-ups from its headquarters in biotech hub COBIS, located in Copenhagen. The company is now seeking to correct this incongruity by aiding the area.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app